Betekenis en Metodologie van Fundamentele Analise (2025)

Dividendbetalende aandele: opbrengs, risiko, strategie

Balansstaat en inkomstestaat duidelik gemaak 2025

Wat is 'n aandelebeurs? Werking, akteurs, voorbeelde

Aandeelwaardasie 2025: 'n Beginnersgids

Objective Corporation (ASX:OCL) aandeelfundamentele aspekte, oorsig



Objective Corporation is 'n Australiese sagtewaremaatskappy wat in 1987 gestig is en spesialiseer in inhoud- en rekordbestuur- en regulatoriese werkvloeisagteware vir die regering en gereguleerde nywerheidsektore (bv. verdedigingsinstellings, weermag, ens.). Die maatskappy word vandag steeds deur stigter Tony Walls gelei, wat ongeveer 64.81% van die aandele besit deur die TBW Group-houermaatskappy, een van die hoogste stigter

Objective Corporation (ASX:OCL) aandeelfundamentele aspekte, oorsig



Objective Corporation is 'n Australiese sagtewaremaatskappy wat in 1987 gestig is en spesialiseer in inhoud- en rekordbestuur- en regulatoriese werkvloeisagteware vir die regering en gereguleerde nywerheidsektore (bv. verdediging

Objektiewe Korporasie Aandeelanalise – Staat Binne Staat

Wat bevat die aandelemarkverslagafdeling?



Die aandeelprys het bestendig gedaal voor die Computer Modelling Group se 2027 K1-verslag, aangesien die transformasie van die volwasse oliemaatskappy in 'n reeksverkrygingsmaatskappy langer neem as verwag. Daarom verdien dit 'n plek in die afdeling "Verslaggewing van die Effektebeurs", wat altyd 'n opdatering oor fundamentele analise is. Maar waaroor gaan dit alles?



Die kolom is 'n soort kompas vir beleggers wat hulle help om deur die digte datast

Wat bevat die aandelemarkverslagafdeling?



Die aandeelprys het bestendig gedaal voor die Computer Modelling Group se 2027 K1-verslag, aangesien die transformasie van die volwasse oliemaatskappy in 'n reeksverkrygingsmaatskappy langer neem as verwag. Daarom verdien dit 'n plek in die afdeling "Vers

Rekenaarmodelleringsgroep 2027 K1 - Omkeerpunte draai selde?

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

The trust seeks to achieve its investment objective by holding a portfolio of the common stocks that are included in the index (the "Portfolio"), with the weight of each stock in the Portfolio substantially corresponding to the weight of such stock in the index.

Pfizer: Poised For Gains With A New Drug Pipeline And Cost-Cutting Plans

FDA commissioner nominee Overton rebuffs questions about Trump medical claims

BridgeBio says heart disease therapy Attruby beat Pfizer’s Vyndamax in real world study

Pfizer: A Quietly Outperforming High-Dividend Idea, Pipeline On Watch (Upgrade)

Pfizer Inc. (PFE) Presents at U.S. All Stars Conference Transcript

Pfizer: A Conservative Valuation Leaves Room For A Post-LOE Re-Rating

Pfizer: Stagnant Dividends At Rich Yields - Income Before Appreciation

Pfizer: The Market Won't Pay For 2029 Until It Can - Downgrading To Hold

Pfizer: The 10-Year Is At 5%, And I'm Still Buying This 6%+ Yield

Pfizer to share higher overseas drug revenue with U.S. under new HHS contract: report

RFK Jr. replaces federal autism panel chair: report

Trump to 'demand' vaccine makers make smaller doses for kids to address autism

Trump announces MFN pricing for Medicaid in all states

Trump administration is said to weigh allowing most pharma licensing deals with China

HHS to launch autism research initiative utilizing AI: report

FDA launches pilot program that aims to speed the time to first-in-human drug trials

Pfizer Inc. (PFE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Pfizer: Firing On All Cylinders

Novartis India inks $132M asset purchase deal with Pfizer for Minipress brands

RFK Jr. is probing if U.S. troops died of COVID shots: report

Pfizer, Medicus ink licensing deal worth up to $1B for antibody drug conjugate

Pfizer-backed Priovant wins FDA approval for lead asset

Pfizer, BioNTech win approval for updated COVID-19 shot

HHS advisors to discuss boosting funding for autism care

SA Asks: What are the most promising oncology companies right now?

HHS seeking public input on vaccine recommendation categories

Lawmakers ask FDA to scrutinize Chinese trials amid deaths - report

Pfizer: Patient Investors Will Be Rewarded

New CDC director says vaccines are 'safe and effective'

Trump nominates White House adviser Overton as next FDA commissioner

Covid-19 vaccine comments

segment-revenues

Segment Revenues ($M)

Szegmens Árbevételek ($M)

geographic-revenues

Geographic Revenues ($M)

Bevétel Földrajzi Megoszlás ($M)

Rekeninge betaalbaar

Totale bedryfsbates

Kontant

Kort/huidige langtermynskuld

Klandisiewaarde

Ontasbare bates

Netto tasbare bates

Eiendom, aanleg en toerusting

Netto debiteure

Aandeelhouersbelang

Totale bates

Totale bedryfslaste

Totale laste

Balansstaat

Kapitale uitgawes (TTM)

Bedryfskontantvloei (TTM)

Dividende betaal (TTM)

Vrye kontantvloei (TTM)

Kontantvloei

DGR 10 jare

DGR 15 jare

DGR 3 jare

DGR 5 jare

DGR MR

DGR TTM

EPS groei (5j vorentoe)

EPS groei (5j)

Tyd sedert laaste verandering aangekondig

Dividendgroei

Gemiddelde opbrengs

Opbrengs as % van maksimum opbrengs

Afslag tot gemiddelde opbrengs

Dividend per aandeel

Dividendopbrengs

Uitbetaling frekwensie

Maksimum opbrengs

Minimum opbrengs

Opwaartse potensiaal

Dividend opbrengs - 5j

Gemiddelde tyd tot nuwe hoogtepunt

Gemiddelde daling vanaf hoogtepunt

Maksimum tyd tot nuwe hoogtepunt

Hoogste prysdaling

Datum van hoogste daling

Huidige prysdaling vanaf die hoogste punt van alle tye

Afwaartse potensiaal

CCC status

Jare van groei

EPS (1j vorentoe)

EPS (TTM)

Ex-dividend datum

Kontant opbrengs op belegde kapitaal

Opbrengs op bates

Opbrengs op ekwiteit

Opbrengs op belegde kapitaal

Finansiële opbrengste

Bruto wins (TTM)

Netto inkomste (TTM)

Bedryfsinkomste (TTM)

Inkomste (TTM)

Inkomstestaat

Bruto marge (TTM)

Bedryfsmarge (TTM)

Winsgrens (TTM)

Marges

Gemiddeld

Vorentoe

Uitbetalingverhouding

FCF per aandeel (TTM)

Huidige aandeeltelling

Per aandeel

Huidige opbrengsverspreiding

Opbrengs by 0% (Max)

Opbrengs by 10%

Opbrengs by 100% (Min)

Opbrengs by 20%

Opbrengs by 50% (Mediaan)

Opbrengs by 80

Opbrengs by 90%

Opbrengsverdeling (omgekeerde persentiel) - 5j

Hoogtepunt van alle tye

1j analiseraaming

Beta

Prys by sluiting

Daaglikse hoog

Daaglikse laag

Open

Daaglikse volume

Volgende verdienste datum

Aandele grafiek

EV tot verkope

Prys tot Boekwaarde

Prys tot verkope

Waardering (Verkope/Boekwaarde)

EV tot EBITDA

Agterlopende P/E

Prys tot EBITDA

Prys tot FCF

Prys tot OCF

Waarderingsverhoudings

PFE

Objektiewe Korporasie Aandeelanalise – Staat Binne Staat

Besigheid insig

Betekenis en Metodologie van Fundamentele Analise (2025)

Segment Revenues ($M)

Geographic Revenues ($M)